NumFin

Arrowhead Pharmaceuticals, Inc.

符号: ARWR

NASDAQ

24.44

USD

今天的市场价格

  • -8.8447

    市盈率

  • 0.1429

    PEG比率

  • 3.03B

    MRK市值

  • 0.00%

    DIV收益率

Arrowhead Pharmaceuticals, Inc. (ARWR) 财务报表

Download
年度季度
线性对数
在图表中，您可以看到 的动态默认数字 Arrowhead Pharmaceuticals, Inc. (ARWR). 的默认数据。公司收入显示 34.687 M 的平均值，即 7.711 % 增长率。整个期间的平均毛利润为 33.808 M，即 7.752 %. 平均毛利率为 0.866 %. 公司去年的净收入增长率为 0.163 %，等于 -0.900 % % 整个公司历史的平均增长率.,

年度季度
10Y20Y30Y40Y

资产负债表

深入分析 Arrowhead Pharmaceuticals, Inc. 的财务轨迹，我们可以看到其平均资产增长率。有趣的是，这一增长率为 ，反映了公司的高点和低点。与季度相比，这一数字调整为0. 回顾过去一年，总资产变化为 0.106. 在流动资产领域，ARWR 的报告货币为110.891. 这些资产中的很大一部分，即 110.891 是现金和短期投资。与去年的数据相比，该部分的变化率为-0.705%. 公司的长期投资虽然不是其重点，但以报告货币计算的292.735（如果有的话）为292.735。这表明与上一报告期相比，176.499% 的差异反映了公司的战略转变. 公司的债务概况显示，以报告货币计算的长期债务总额为 104.608. 这一数字表明，0.412% 的年同比变化. 股东权益总额所体现的股东价值是以报告货币计算的 271.343. 这方面的年同比变化率为 1.561%. 深入了解公司财务信息后，会发现更多细节。应收账款净额的估值为0，存货估值为 0，商誉估值为 0（如有. 无形资产总额（如果有）按 10.26 估值.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000199919981997

balance-sheet.row.cash-and-short-term-investments

1556.61110.9376.4367.8
315.5
258.7
76.5
65.6
85.4
98.8
154.2
28.1
3.5
8.1
6.8
2
10.1
24.1
28
22.5
9
1.4
0
0
0
0
0
0

balance-sheet.row.short-term-investments

1147.21292.7268.4183.4
171.9
36.9
46.4
40.8
0
17.5
21.7
9
0.1
0.6
0
0
0
0
0
0.1
0.5
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

70.6801.410.3
0.8
0.7
0.3
0.1
0.1
0
0
0.1
2.5
1.6
0.9
0.1
0.1
0.3
0.1
0
0.1
0
0
0
0
0
0
0

balance-sheet.row.inventory

19.990-21.64.4
4.3
3.3
1.3
0.9
1.3
0
0
0
0
0
0.2
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-current-assets

35.787.120.22.2
1.8
2.6
0.6
1.4
3.8
0.8
0
0.6
0.6
0.1
0.1
0.3
0.4
0.9
0.7
0.2
0.4
0.2
0
0
0
0
0
0

balance-sheet.row.total-current-assets

1702.39110.9376.4384.6
322.4
265.2
78.8
67.9
90.5
102.9
154.8
28.8
6.6
9.9
8.1
2.5
10.6
25.3
28.8
22.8
9.5
1.5
0
0
0
0
0
0

balance-sheet.row.property-plant-equipment-net

1212.26335.6168.666
47
23.2
13.9
15.5
15.4
4.5
3.9
3.5
4.9
0
0.1
0.5
1.2
1.4
1.3
1.1
0.9
0
0
0
0
0.1
0
0.1

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1.8
0.4
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

41.910.31213.7
15.4
17.1
18.8
20.5
22.2
24.8
1
3.2
4.8
1.7
2
2.4
2.7
2.9
3.4
5
1.5
0
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

41.910.31213.7
15.4
17.1
18.8
20.5
22.2
24.8
1
3.2
4.8
1.7
2
2.4
2.7
2.9
4.3
5
1.5
0
0
0
0
0
0
0

balance-sheet.row.long-term-investments

121.59292.7105.9245.6
137.5
44.2
0
0
0
0
23.1
0
0
1.8
2
2.2
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

0-345.800
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

0.86361.929.10.3
0.3
0.1
0.1
0.1
0.1
0
0
1.7
0.3
2.4
0
0.1
2.7
0.2
0.2
0.1
0.1
0
0
0
0
0
0
0

balance-sheet.row.total-non-current-assets

1376.61654.7315.5325.6
200.1
84.6
32.8
36.1
37.7
29.4
28
8.5
10
6
4.2
5.2
6.7
4.5
5.8
6.2
2.4
0
0
0
0
0.1
0.1
0.1

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

3079765.6691.9710.1
522.5
349.8
111.6
104
128.2
132.3
182.8
37.3
16.5
15.9
12.4
7.7
17.3
29.9
34.5
29
11.9
1.5
0.1
0
0.1
0.1
0.1
0.1

balance-sheet.row.account-payables

57.7635.92.99.5
6.8
7.6
2.8
4.1
12.2
5
2.6
1.2
0.9
0.6
0.7
1
1.3
1.3
0.8
0.5
0.5
0.1
0.3
0.2
0.2
0.2
1.1
1.4

balance-sheet.row.short-term-debt

19.5210.62.82.3
1.1
11.6
0.2
0.2
0.2
0.2
0.3
1.2
0.2
0
0.5
0.7
0.8
1
0
0
0
0
0.6
0.5
0.5
0.5
1
1

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

379.75104.678.823.3
20
0
2.1
2.3
2.5
0.5
0.8
1.1
2.1
0.6
0
0.5
0.7
0
0
0
0
0
0
0
0
0
0.3
0

Deferred Revenue Non Current

1.07056131.5
0
5
0
0
2.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

146.29-46.4-5.623.8
13.5
0
9.3
9.1
10.6
10.5
8.9
6.2
4.2
2
2.4
0.2
0.5
0.4
2.1
0.4
0.1
0
0.7
0
0.5
0.3
0.3
0.2

balance-sheet.row.total-non-current-liabilities

1444.48477.5511.9154.8
20
8.7
4
4.5
7.5
6.7
5
2.9
2.4
0.7
0
0.5
1.2
0.5
934.4
1.9
1.8
0
0
0
0
0
0
0

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-934.4
-1.9
-1.8
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

399.26115.281.625.5
21.1
0
0
0
0
0.8
1
1.3
1.5
0
0
0.7
0.7
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

1771.04478.4586301.3
60.7
105.8
16.4
23.2
33.2
22.6
16.8
11.6
7.7
3.3
4.3
2.8
5
3.4
2.9
1
0.7
0.1
1.6
1.4
1.2
1.1
2.7
2.7

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1162
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

0.80.21060.2
0.2
0.2
0.2
0.2
0.2
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.retained-earnings

-3914.68-1026-820.8-644.7
-503.8
-419.3
-487.3
-432.8
-398.4
-316.7
-224.8
-166.1
-135
-113.9
-110.7
-105
-85.5
-58.4
-28.5
-9.2
-2.6
-0.1
-9.6
-9.4
-9.2
-9
-9.5
-9.4

balance-sheet.row.accumulated-other-comprehensive-income-loss

-5.22-3.2-0.1-0.1
0
-0.4
0
0
0
-0.1
-4.2
-3.1
-1.6
-0.3
-1.2
-1
-1.6
-1.7
-1.1
-0.7
-0.2
0
-0.1
0
-0.1
-0.1
-0.1
-0.1

balance-sheet.row.other-total-stockholders-equity

5162.451300.4820.91053.4
965.4
664.1
582.9
514
493.8
426.9
395.4
196.6
146.5
126.9
120.9
110.8
99.4
86.3
-1101.8
36
12.2
1.5
8.1
8.1
8.1
8.1
6.9
6.9

balance-sheet.row.total-stockholders-equity

1243.35271.3106408.8
461.8
244.6
95.8
81.4
95.6
110.2
166.5
27.5
10
12.8
9
4.9
12.3
26.3
30.7
26.1
9.4
1.4
-1.6
-1.3
-1.1
-1
-2.6
-2.6

balance-sheet.row.total-liabilities-and-stockholders-equity

3079765.6691.9710.1
522.5
349.8
111.6
104
128.2
132.3
182.8
37.3
16.5
15.9
12.4
7.7
17.3
29.9
34.5
29
11.9
1.5
0.1
0
0.1
0.1
0.1
0.1

balance-sheet.row.minority-interest

64.6115.819.80
0
-0.6
-0.6
-0.6
-0.6
-0.6
-0.6
-1.8
-1.2
-0.2
-1
0
0
0.2
0.9
1.9
1.8
0
0
0
0
0
0
0

balance-sheet.row.total-equity

1307.97287.2125.8408.8
461.8
244
95.2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

3079---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

1268.81292.7374.3428.9
309.4
81.1
46.4
40.8
0
17.5
44.7
9
0.1
2.5
2
2.2
0
0
0
0.1
0.5
0
0
0
0
0
0
0

balance-sheet.row.total-debt

399.26115.281.625.5
21.1
0
2.3
2.5
2.7
0.8
1
2.3
2.3
0.6
0.5
1.2
1.5
0
1.2
0
0
0
0.6
0.6
0.6
0.6
1.3
1

balance-sheet.row.net-debt

-10.134.3-26.4-158.9
-122.4
-221.8
-27.8
-22.3
-82.6
-80.5
-131.5
-16.8
-1
-6.9
-6.3
-0.8
-8.6
-24.1
-26.8
-22.5
-8.6
-1.4
0.6
0.6
0.6
0.6
1.3
1

现金流量表

在 Arrowhead Pharmaceuticals, Inc. 的财务状况中，自由现金流在过去一段时间内发生了显著变化，呈现出 -0.750 的转变。该公司最近通过发行 3.05 扩大了股本，与上一年相比出现了-99.811 的差异. 有趣的是，公司的部分股票，特别是 0，是由公司自己回购的。这一举动导致0.000 比上一年有所变化。同时，以报告货币计算，公司的应付账款目前为 33. 公司的投资活动产生了现金使用净额，按报告货币计算达到-96155000.000. 与上一年相比， 16.751 发生了变化. 在同一时期，公司记录了 12.49, 80.58 和 -250，这对于了解公司的投资和还款策略具有重要意义. 公司的融资活动导致使用的现金净额为0.000，同比差异为0.000. 此外，公司还将0 用于向股东分红。与此同时，该公司还采取了其他财务措施，即 500，这也对其在此期间的现金流产生了重大影响. 这些组成部分合在一起，全面反映了公司的财务状况和现金流管理的战略方针。

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000199919981997

cash-flows.row.net-income

-302.84-209.3-176.5-140.8
-84.6
68
-54.5
-34.4
-81.7
-91.9
-58.6
-31.1
0
-8.8
-6.2
-19.3
-27.1
-29.9
-19
-6.6
-2.5
-0.1
-0.2
-0.2
-0.1
0.6
-0.1
-0.9

cash-flows.row.depreciation-and-amortization

14.0712.510.48.3
5.9
4.4
4.7
4.7
3.3
2.3
1.3
1.8
1.7
0.3
0.7
1
1.1
1
0.9
0.6
0.1
0
0
0
0
0
0
0.1

cash-flows.row.deferred-income-tax

-2.93-34.400
0
0
-0.4
-0.9
2.4
-2.9
8.1
7.7
-0.6
1.5
0
-1.3
0
0
-1371.1
0
-0.1
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

78.4378.1120.976.7
43.4
12.4
8.5
7.9
11.6
10.2
5.7
1.5
1.2
1.4
1.6
2.7
0
0
1369.5
0
0.1
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

-3.1-51.5-98.3226.9
-60.7
87.2
-5.9
-1.2
5.7
3.4
5
0.1
0.2
0
-1
-0.8
-0.2
0
1.4
0.4
0
-0.1
0.2
0.2
0
0.1
0
0.1

cash-flows.row.account-receivables

39.571.48.8-9.4
-0.2
-0.3
-0.3
0
-0.1
0
0.1
-0.1
162.9
0
0
-60.7
0
0
-40.8
0
-0.1
0
0
0
0
0
0
0

cash-flows.row.inventory

2.4-3.409.2
1.6
-1.3
1.3
2.4
-1.9
0
-139.4
-20.2
-162.9
0
0
60
0
0
-328.3
0
-9
0
0
0
0
0
0
0

cash-flows.row.account-payables

22.6133-6.62.6
-0.8
4.8
-1.3
-3.5
2.6
2.5
1.4
0.3
0.3
0.2
-0.3
-0.3
0
0
370.4
0
0.2
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

-67.67-82.6-100.5224.5
-61.3
83.9
-5.7
-0.1
5.1
0.9
143
20.1
0
-0.2
-0.7
0.1
-0.2
0
0.1
0.4
8.8
-0.1
0.2
0.1
0
0.1
0
0.1

cash-flows.row.other-non-cash-items

20.1550.77.30.3
0.5
1.1
0.4
0
-5.6
13.1
3.1
1
-18
0.2
-2.7
2.5
-1.4
5
3.6
-3.6
0.1
0
-0.1
-0.1
0
-0.7
0
0.7

cash-flows.row.net-cash-provided-by-operating-activities

-196.21000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-206.48-176.7-52.8-23.6
-12
-12
-1.4
-7.9
-3.9
-2
-1.7
-0.3
-0.5
0
0
0
-0.7
-0.8
-0.9
-0.7
-0.7
0
0
0
0
0
0
0

cash-flows.row.acquisitions-net

-122.36-80.6-47.4141.7
240777.8
47746
7435
0
0
-10
0
0
0.1
-1.7
0
0
0.1
5.1
205.1
-8
0.3
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

-134.94-246.1-223.4-240.7
-279
-90.3
-52.1
-45
0
0
-46.4
-10.7
0
1700.4
0
0
0
0
-18.6
2.4
0
0
0
0
0
0
0
0

cash-flows.row.sales-maturities-of-investments

390.8326.7270.8122.6
50.1
54.5
46.1
4.2
17.3
26.1
11.6
1.4
0.5
1.5
0
0.7
0
0
19
0.5
0
0
0
0
0
0
0
0

cash-flows.row.other-investing-activites

255.8680.647.4-141.7
-240777.8
-47746
-7435
0
0
0
0
0.1
0.3
-1700.4
0.5
0.1
-2
0
-205.1
8
0
0
0
0
0
0
0
0

cash-flows.row.net-cash-used-for-investing-activites

49.38-96.2-5.4-141.7
-240.8
-47.7
-7.4
-48.6
13.4
14.1
-36.5
-9.5
0.4
-0.2
0.5
0.7
-2.6
4.4
-0.5
2.3
-0.4
0
0
0
0
0
0
0

cash-flows.row.debt-repayment

-250-25000
0
-2.4
-0.2
-0.2
-0.2
-0.2
-0.2
-0.2
-0.2
0
-0.7
-0.8
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-issued

1.353.15.211.3
250.5
60.5
56.6
12.4
52.2
0
172.6
44.5
11
6.2
12.2
4.8
16.3
15.6
20.9
20.7
9.9
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

252.185006011.3
7.5
8.3
3.6
-0.2
3.1
0.5
12.9
0
0
0
0.6
2.5
-0.1
0
0
0
0
1.5
0.1
0.1
0.1
0
0
0

cash-flows.row.net-cash-used-provided-by-financing-activities

2.74253.165.211.3
257.9
66.4
60
12.1
55.1
0.3
185.3
44.3
10.8
6.2
12
6.5
16.1
15.6
20.9
20.7
9.9
1.5
0.1
0.1
0.1
0
0
0

cash-flows.row.effect-of-forex-changes-on-cash

0.06-0.1-0.1-0.1
0.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1.4
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

-144.032.9-76.440.9
-78.2
191.7
5.3
-60.5
4.2
-51.3
113.4
15.7
-4.1
0.7
4.8
-8.1
-14
-3.9
5.6
13.9
5.8
1.4
0
0
0
0
0
0

cash-flows.row.cash-at-end-of-period

409.4110.9108184.4
143.6
221.8
30.1
24.8
85.4
81.2
132.5
19.1
3.4
7.5
6.8
2
10.1
24.1
28
22.5
7.2
1.4
0
0
0
0
0
0

cash-flows.row.cash-at-beginning-of-period

553.43108184.4143.6
221.8
30.1
24.8
85.4
81.2
132.5
19.1
3.4
7.5
6.8
2
10.1
24.1
28
22.5
8.6
1.4
0
0
0
0
0
0
0

cash-flows.row.operating-cash-flow

-196.21-153.9-136.1171.2
-95.4
173
-47.2
-23.9
-64.4
-65.7
-35.4
-19
-15.3
-5.4
-7.7
-15.3
-27.6
-23.9
-14.8
-9.1
-2.3
-0.2
-0.1
-0.1
-0.1
0
0
0

cash-flows.row.capital-expenditure

-206.48-176.7-52.8-23.6
-12
-12
-1.4
-7.9
-3.9
-2
-1.7
-0.3
-0.5
0
0
0
-0.7
-0.8
-0.9
-0.7
-0.7
0
0
0
0
0
0
0

cash-flows.row.free-cash-flow

-402.7-330.6-188.9147.7
-107.3
161
-48.6
-31.9
-68.3
-67.7
-37.1
-19.3
-15.8
-5.4
-7.7
-15.3
-28.3
-24.6
-15.7
-9.8
-3
-0.2
-0.1
-0.1
-0.1
0
0
0

利润表行

Arrowhead Pharmaceuticals, Inc. 的收入与上期相比变化了 -0.010%。据报告, ARWR 的毛利润为 228.24。该公司的营业费用为 445.74，与上年相比变化了 5.690%. 折旧和摊销费用为 12.49，与上一会计期间相比变化了 0.199%. 营业费用报告为 445.74，显示5.690% 的同比变化。 销售和营销费用为 0, 其中 0.000% 与上年相比发生了变化。 基于近期数据的EBITDA为 0，同比增长-0.148%. 营业收入为 -205，与上年相比变化了0.148%. 净利润的变化率为 0.163%。去年的净收入为-205.28.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000199919981997

income-statement-row.row.total-revenue

181.74240.7243.2138.3
88
168.8
16.1
31.4
0.2
0.4
0.2
0.3
0.1
0.3
0.6
3.8
1.3
1.2
0.6
0.6
0.2
0
0
0
0
0
0.1
0.1

income-statement-row.row.cost-of-revenue

14.0712.510.40
0
0
0
0
0
0
0
0
0
0
0
0
0
0.7
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.gross-profit

167.67228.2232.8138.3
88
168.8
16.1
31.4
0.2
0.4
0.2
0.3
0.1
0.3
0.6
3.8
1.3
0.5
0.6
0.6
0.2
0
0
0
0
0
0
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

385.98---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

93.54---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

1.851.55.82.1
-0.6
0
0
1.3
0.1
0.4
0.1
-1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.operating-expenses

481.15445.7421.7287.3
181.2
107.6
72.1
68.4
79.9
96.4
51.3
23.6
21.2
10.1
9.4
23.5
36.3
38.4
21.8
10
3
0.1
1.4
0.1
0.1
0.1
0.1
0.2

income-statement-row.row.cost-and-expenses

481.15445.7421.7287.3
181.2
107.6
72.1
68.4
79.9
96.4
51.3
23.6
21.2
10.1
9.4
23.5
36.3
39.2
21.8
10
3
0.1
1.4
0.1
0.1
0.1
0.1
0.2

income-statement-row.row.interest-income

15.4215.356.1
9.2
7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.interest-expense

20.8418.356.1
9190.5
6957.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0.951.55.88.2
8.6
7
0.4
2.2
-2.3
3.3
-8.3
-8.3
-1.1
1
1.5
0.6
-0.1
0
-0.7
2.4
0
0
0.1
0.1
0.1
-0.2
0
-0.7

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

1.851.55.82.1
-0.6
0
0
1.3
0.1
0.4
0.1
-1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.total-operating-expenses

0.951.55.88.2
8.6
7
0.4
2.2
-2.3
3.3
-8.3
-8.3
-1.1
1
1.5
0.6
-0.1
0
-0.7
2.4
0
0
0.1
0.1
0.1
-0.2
0
-0.7

income-statement-row.row.interest-expense

20.8418.356.1
9190.5
6957.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

18.6412.510.48.3
5.9
4.4
4.7
4.7
3.3
2.3
1.3
1.8
1.7
0.3
0.7
1
1.1
1
0.9
0.6
0.1
0
0
0
0
0
0
0.1

income-statement-row.row.ebitda-caps

-268.48---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-299.41-205-178.5-149
-93.2
61.2
-55.9
-37
-81.7
-96
-53.3
-24.6
-21.1
-9.8
-8.8
-19.7
-35
-37.9
-21.2
-9.4
-2.8
-0.1
-1.4
-0.1
-0.1
-0.1
0
-0.2

income-statement-row.row.income-before-tax

-303.39-206.5-172.7-140.8
-84.6
68.1
-54.4
-34.4
-81.7
-91.9
-58.7
-31.7
-22.1
-8.8
-7.3
-19.2
-35.1
-37.9
-21.9
-7
-2.5
-0.1
-0.2
-0.2
-0.1
-0.4
0
-0.9

income-statement-row.row.income-tax-expense

-1.542.83.80
0
0.2
0
0
0
0
0
6.2
-0.2
-6.9
-3.2
0.1
-8
-8
-2.2
-2.7
0
0
-1.2
0.1
0
-0.6
0
0.7

income-statement-row.row.net-income

-296.81-205.3-176.5-140.8
-84.6
68
-54.5
-34.4
-81.7
-91.9
-58.6
-31.1
-21.1
-3.1
-5.8
-19.3
-27.1
-29.9
-19
-6.6
-2.5
-0.1
-0.2
-0.2
-0.1
0.6
-0.1
-0.9
类似股票
您可能还对以下内容感兴趣：
SRNE
Sorrento Therapeutics, Inc..
0.015 USD
NASDAQ
MRVI
Maravai LifeSciences Holdings, Inc..
8.97 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.03 USD
NASDAQ
GUBRA.CO
Gubra A/S.
300 DKK
CPH
T5O.DE
CytoTools AG.
0.468 EUR
XETRA
HBC.OL
Hofseth BioCare ASA.
2.1 NOK
OSL
6826.HK
Shanghai Haohai Biological Technology Co., Ltd..
42.35 HKD
HKSE
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ

常见问题

什么是 Arrowhead Pharmaceuticals, Inc. (ARWR) 总资产是多少？

Arrowhead Pharmaceuticals, Inc. (ARWR) 总资产为 765552000.000.

什么是企业年收入？

年收入为 19648000.000.

企业利润率是多少？

公司利润率为 0.923.

什么是公司自由现金流？

自由现金流为 -3.749.

什么是企业净利润率？

净利润率为 -1.633.

企业总收入是多少？

总收入为 -1.647.

什么是 Arrowhead Pharmaceuticals, Inc. (ARWR) 净利润？{{符号}}净利润（净收入）是多少？

净利润（净收入）为 -205275000.000.

公司总债务是多少？

债务总额为 115171000.000.

营业费用是多少？

运营支出为 445737000.000.

公司现金是多少？

企业现金为 58215000.000.